Abstracts tagged "rheumatoid arthritis"

Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: 511 • 2019 ACR/ARP Annual Meeting
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Maya H. Buch¹, Alvin F. Wells ², Andrea Rubbert-Roth ³, Manish Jain ⁴, Casey Schlacher ⁵, Heidi Camp ⁵, Yihan Li ⁵, Yanna Song ⁶ and Peter Nash ⁷, ¹University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology and Immunotherapy Center, Franklin, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy and safety in patients with rheumatoid arthritis (RA) as monotherapy and in combination with conventional…
Abstract Number: 816 • 2019 ACR/ARP Annual Meeting
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Muriel Elhai¹, Raphael Micheroli ¹, Mojca Frank-Bertoncelj ², Kerstin Klein ¹, Oliver Distler ³ and Caroline Ospelt ², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Zürich, Switzerland, ²University Hospital Zürich, Zürich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Mechanisms involved in joint patterning of rheumatic diseases remain unknown. The long non-coding RNA HOTAIR is exclusively expressed in synovial fibroblasts (SF) from lower…
Abstract Number: 999 • 2019 ACR/ARP Annual Meeting
Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy
Rakeshchandra Meka¹, Shivaprasad Venkatesha ¹, Bodhraj Acharya ¹ and Kamal Moudgil ¹, ¹University of Maryland School of Medicine and Baltimore VA Medical Center, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease characterized by inflammation of the synovial tissue of the joints, which if not controlled early…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Shuji Asai¹, Toshihisa Kojima ¹, Nobunori Takahashi ¹ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
Abstract Number: 6 • 2019 ACR/ARP Annual Meeting
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹ and Salahuddin Ahmed ², ¹Washington State University Spokane, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…
Abstract Number: 513 • 2019 ACR/ARP Annual Meeting
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Josef Smolen¹, Paul Emery ², William Rigby ³, Yoshiya Tanaka ⁴, Juan Ignacio Vargas ⁵, Nemanja Damjanov ⁶, Manish Jain ⁷, Yunxia Sui ⁸, Jose Jeffrey Enejosa ⁹, Aileen Pangan ¹⁰, Heidi Camp ⁹ and Stanley Cohen ¹¹, ¹Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Dartmouth-Hitchcock Medical Center, Lebanon, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁷Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁸AbbVie Inc., Chicago, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…
Abstract Number: 817 • 2019 ACR/ARP Annual Meeting
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Shunsei Hirohata¹, Tatsuo Nagai ², Tetsuya Tomita ³ and Hideki Yoshikawa ³, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Tatsuno, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Osaka University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, consisting of type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes (FLS).…
Abstract Number: 1000 • 2019 ACR/ARP Annual Meeting
RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Sang-Il Lee¹, Hae Sook Noh ² and Yun-Hong Cheon ¹, ¹Divison of Rheumatology, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea, ²Gyeongsang University Hospital, Jinju, Republic of Korea
Background/Purpose: Nuclear factor-kappaB (NF-kappaB) and extracellular-signal-regulated kinase (ERK) have been implicated as a therapeutic target for the treatment of rheumatoid arthritis (RA). Raf kinase inhibitory…
Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Toshihisa Kojima¹, Shuji Asai ¹, Masahiro Hanabayashi ², Masatoshi Hayashi ³, Nobunori Takahashi ¹, Yachiyo Kuwatsuka ⁴, Masahiko Ando ⁴ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Ichinomiya Municipal Hospital, Ichinomiya, Japan, ³Hayashi Orthopedic Clinic, Nagano, Japan, ⁴Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…
Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Raj Vachhani¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo¹, Israel Nieto-Gañán ², Cristina Sobrino ³, Victoria Navarro-Compán ⁴, Ana Martínez-Feito ⁵, Carlota García-Hoz ⁶, Paloma Lapuente-Suanzes ², javier Bachiller ³, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ³, Garbiñe Roy ², Mónica Vázquez Díaz ³, Alejandro Balsa ⁷, Luisa María Villar ², Dora Pascual-Salcedo ¹, Eulalia Rodríguez-Martín ² and Chamaida Plasencia ⁷, ¹Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ³Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁶Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
Abstract Number: 35 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis
Yuko Okamoto¹, Elena W.Y. Hsieh ², Ronald P. Schuyler ³, Jennifer Seifert ⁴, Marie Feser ⁵, Jill Norris ⁶, M. Kristen Demoruelle ⁷, Kevin Deane ⁵ and V. Michael Holers ⁴, ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA and Tokyo Women’s Medical University School of Medicine, Department of Rheumatology, Tokyo, Japan, Denver, ²University of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, USA and University of Colorado School of Medicine, Children’s Hospital Colorado, Department of Pediatrics, Section of Allergy & Immunology, Aurora, CO, USA, Denver, ³University of Colorado School of Medicine, Department of Immunology and Microbiology Aurora, CO, USA, Denver, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁶Colorado School of Public Health, Department of Epidemiology, Aurora, CO, USA, Denver, ⁷University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Our group previously demonstrated that sputum neutrophils from subjects At-Risk for future rheumatoid arthritis (RA) spontaneously form neutrophil extracellular traps with elevated histone H3…

1
2
3
…
26
Next Page »